Heparin prophylaxis of gestational complications in women with Factor V Leiden mutation (GA genotype)
https://doi.org/10.17749/2313-7347.2018.12.2.021-031
Abstract
The aim of the study was to determine the efficacy of heparin prophylaxis in preventing pregnancy complications in patients with the manifested laboratory phenotype – resistance to activated protein C (APC-resistance with NR ≤ 0.49) Factor V Leiden mutation (GA genotype). Materials and methods. A single-center, randomized, controlled trial of 141 pregnant women – carriers of the FVL(1691)GA mutation with APC-resistance ≤ 0.49 was determined at a gestation age of 7-8 weeks. Of these, 70 patients were included in the main group (mean age 30.2 ± 4.7 years); after the confirmation of the APC-resistance at 7-8 weeks of gestation, these women received a 14 day low-molecular-weight heparin (LMWH) course at elevated prophylactic doses. The comparison group (71 pregnant women of 30.3 ± 3.9 years old) received no LMWH. Results. The heparin prophylaxis (started from 7-8 weeks of gestation) at elevated doses in carriers of the FVL(1691)GA mutation with pronounced APC-resistance reduced the absolute risk (ARR) of pre-eclampsia by 29.5% (ARR: 29.5; p = 0.0003; NTT: 3.4; 95% Cl: 2.356.12), the risk of fetal growth retardation by 23.8% (ARR: 23.8; p = 0.0016; NTT: 4.2; 95% Cl: 2.8-8.7) and the risk of induced premature birth by 12.6% (ARR: 12.6; p = 0.0242; NTT: 5.8; 95% Cl: 3.7-14.1). Conclusion. The administration of LMWH at prophylactic doses for 14 days is indicated in patients with a manifested subclinical (laboratory) phenotype (APC-resistance with NR ≤ 0.49) of the FVL(1691)GA mutation starting from the gestation period of 7-8 weeks. If necessary (with a value of NR ≤ 0.49), it is advisable to repeat the courses of heparin prophylaxis at 18-19 and 27-28 weeks of pregnancy.
About the Authors
M. G. Nikolaeva
Altai State Medical University, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Nikolaeva Mariya Gennad'evna – PhD, Associate Professor, Department of Obstetrics and Gynecology
40, pr. Lenina, Barnaul, 656038
A. P. Momot
Altay Branch of National Research Center for Hematology, Health Ministry of Russian Federation
Russian Federation
Russian Federation
Momot Andrey Pavlovich – MD, Professor, Director
1, ul. Lyapidevskogo, Barnaul, 656045
M. S. Zainulina
I.P. Pavlov First Saint Petersburg State Medical University, Health Ministry of Russian Federation;
Maternity Hospital № 6 named after professor V.F. Snegirev
Russian Federation
Russian Federation
Zainulina Marina Sabirovna – MD, Professor, Department of Obstetrics, Gynecology and Reproduction, I.P. Pavlov FSPb SMU HM of RF; Physician-in-Chief of Snegirev Maternity Hospital № 6
1, ul. Lyapidevskogo, Barnaul, 656045,
5, ul. Mayakovskogo, Saint Petersburg, 192014
K. A. Momot
Altai Regional Clinical Hospital
Russian Federation
Russian Federation
Momot Ksenia Andreevna – Hematologist
1, ul. Lyapidevskogo, Barnaul, 656045
N. N. Yasafova
Altai Regional Clinical Hospital
Russian Federation
Russian Federation
Yasafova Natalya Nikolaevna – Hematologist
1, ul. Lyapidevskogo, Barnaul, 656045
References
1. Momot A.P. The problem of thrombophilia in clinical practice. [Problema trombofilii v klinicheskoj praktike]. Rossijskij zhurnal detskoj gematologii i onkologii. 2015; 2 (1): 36-48 (in Russian). DOI: 10.17650/2311-12672015-1-36-48.
2. Brosens I., Pijnenborg R., Vercruysse L., Romero R. The «Great Obstetrical Syndromes» are associated with disorders of deep placentation. Am J Obstet Gynecol. 2011; 204: 3: 193-201. DOI: 10.1016/j.ajog.2010.08.009.
3. Halford-Knyazeva I.P., Radzinsky V.E., Samokhodskaya L.M., Yarovaya E. Genetic markers for predicting preeclampsia. [Geneticheskie markery prognozirovaniya preeklampsii]. Doktor.Ru. 2013; 7 (85): 58-66 (in Russian).
4. Di Renzo G.C. The great obstetrical syndromes. J Matern Fetal Neonatal Med. 2009; 22 (8): 633-5. DOI: 10.1080/14767050902866804.
5. Wang X., Bai T., Liu S. et al. Association between Thrombophilia Gene Polymorphisms and Preeclampsia: A Meta-Analysis. PLoS One. 2014; 9 (6): e100789. DOI: 10.1371/journal. pone.0100789.
6. Dissanayake V.H., Weerasekera L.Y., Gammulla C.G., Jayasekara R.W. Prevalence of genetic thrombophilic polymorphisms in the Sri Lankan population – implications for association study design and clinical genetic testing services. Exp Mol Pathol. 2009; 87 (2): 159-62. DOI: 10.1016/j.yexmp.2009.07.002.
7. Rosendaal F.R., Reitsma P.H. Genetics of venous thrombosis. Thromb Haemost. 2009; 7 (Suppl 1): 301-4. DOI: 10.1111/j.1538-7836.2009.03394.x.
8. Bertina R.M., Koeleman B.P., Koster T. et al. Mutation in blood coagulation factor V associated with resistance to activated protein C. Nature. 1994; 369 (6475): 64-7. DOI: 10.1038/369064a0.
9. Makatsariya A.D., Bitsadze V.O., Khizroeva D.Kh. et al. Thromboprophylaxis in pregnant women with thrombophilia and thrombosis in the anamnesis. [Tromboprofilaktika u beremennyh s trombofiliej i trombozami v anamneze]. Byulleten' Sibirskogo otdeleniya RAMN. 2013; 33 (6): 99-109 (in Russian).
10. Bitsadze V.O., Makatsariya A.D., Khizroeva D. Kh. et al. Thrombophilia as the most important link in the pathogenesis of pregnancy complications. [Trombofiliya kak vazhnejshee zveno patogeneza oslozhnenij beremennosti]. Prakticheskaya medicina. 2012; 5 (60): 22-9 (in Russian).
11. Alexandrova N.V., Baev O.R. The early stages of the formation of the mother-placenta-fetus system. [Rannie etapy stanovleniya sistemy mat'-placenta-plod]. Akusherstvo i ginekologiya. 2011; 8: 4-10 (in Russian).
12. Mosnier L.O., Zlokovic B.V., Griffin J.H. The cytoprotective protein C pathway. Blood. 2007; 109 (8): 3161-72. DOI: 10.1182/blood2006-09-003004.
13. Venous thromboembolism, thrombophilia, antithrombotic therapy and pregnancy: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines (8th Edition). Chest. 2008; 133; 844-86. DOI: 10.1378/chest.08-0761.
14. Quenby S., Mountfield S., Cartwright J.E. et al. Effects of low-molecular weight and unfractionated heparin on trophoblast function. Obstet Gynecol. 2004; 104: 354-61.
15. Bose P., Black S., Kadyrov M. et al. Heparin and aspirin attenuate placental apoptosis in vitro: implications for early pregnancy failure. Am J Obstet Gynecol. 2005; 192: 23-30.
16. Bose P., Black S., Kadyrov M. et al. Adverse effects of lupus anticoagulant positive blood sera on placental viability can be prevented by heparin in vitro. Am J Obstet Gynecol. 2004; 191: 2125-31.
17. Chen Y., Wu X.X., Tan J.P. et al. Effects of low molecular weight heparin and heparin-binding epidermal growth factor on human trophoblast in first trimester. Fertil Steril. 2012; 97 (3): 764-70. DOI: 10.1016/j.fertnstert.2011.12.002.
18. Gris J.C., Mercier E., Quere I. et al. Low-molecularweight heparin versus low-dose aspirin in women with one fetal loss and a constitutional thrombophilic disorder. Blood. 2004; 103 (10): 3695-9. DOI: 10.1182/blood-2003-12-4250.
19. Badawy A.M., Khiary M., Sherif L.S. et al. Low-molecular weight heparin in patients with recurrent early miscarriages of unknown aetiology. J Obstet Gynaecol. 2008; 28 (3): 280-4. DOI: 10.1080/01443610802042688.
20. Rey E., Garneau P., David M. et al. Dalteparin for the prevention of recurrence of placentamediated complications of pregnancy in women without thrombophilia: a pilot randomized controlled trial. J Thromb Haemost. 2009; 7 (1): 58-64.
21. Rodger M.A., Hague W.M., Kingdom J. et al. Antepartum dalteparin versus no antepartum dalteparin for the prevention of pregnancy complications in pregnant women with thrombophilia (TIPPS): a multinational open-label randomized trial. Lancet. 2014; 384 (9955): 1673-83. DOI: 10.1016/S01406736(14)60793-5.
22. Martinelli I., Ruggenenti P., Cetin I. et al. Heparin in pregnant women with previous placenta-mediated pregnancy complications: a prospective, randomized, multicenter, controlled clinical trial. Blood. 2012; 119 (14): 3269-75. DOI: 10.1182/blood-201111-391383.
23. Haddad B., Winer N., Chitrit Y. et al. Enoxaparin and aspirin compared with aspirin alone to prevent placenta-mediated pregnancy complications: a randomized controlled trial. Obstet Gynecol. 2016; 128 (5): 1053-63. DOI: 10.1097/AOG.0000000000001673.
24. Visser J., Ulander V.M., Helmerhorst F.M. et al. Thromboprophylaxis for recurrent miscarriage in women with or without thrombophilia. HABENOX: a randomized multicente trial. Thromb Haemost. 2011; 105(2): 295-301. DOI: 10.1160/TH10-05-0334.
25. Kaandorp S.P., Goddijn M., van der Post J.A. et al. Aspirin plus heparin or aspirin alone in women with recurrent miscarriage. N Engl J Med. 2010; 362 (17): 1586-96. DOI: 10.1056/NEJMoa1000641.
26. Nikolaeva M.G., Momot A.P., Serdyuk G.V. et al. APS-resistance associated with factor V Leiden gene mutation (genotype GA): clinical realization in pregnancy. [APS-rezistentnost', svyazannaya s mutaciej gena faktor V Lejden (genotip GA): klinicheskaya realizaciya pri beremennosti]. Tromboz, gemostaz i reologiya. 2018; 1: 47-54 (in Russian). DOI: 10.25555/THR.2018.1.0823.
27. Clinical recommendations «Prevention of venous thromboembolic complications in obstetrics and gynecology» (protocol of treatment). [Klinicheskie rekomendacii «Profilaktika venoznyh tromboembolicheskih oslozhnenij v akusherstve i ginekologii» (protokol lecheniya)]. Pis'mo Ministerstva zdravoohraneniya Rossijskoj Federacii ot 27.05.2014 № 15-4/10/2-3792 (in Russian). URL: http://mzdrav.rk.gov.ru/file/tromboembolicheskie_oslojneniya.pdf. [Accessed: 22.05.2018].
28. GOST R ISO 24153-2012 Statistical methods. Randomization and random sampling procedures. [Statisticheskie metody. Procedury randomizacii i otbora sluchajnoj vyborki] (in Russian). URL: docs.cntd.ru/document/gost-r-iso-24153-2012. [Accessed: 22.05.2018].
29. Hemker H., Giesen P., Al Dieri R. et al. Calibrated automated thrombin generation measurement in clotting plasma. Pathophysiol Haemost Thromb. 2003; 33 (1): 4-15. DOI: 10.1159/000071636.
30. Clinical recommendations «Hypertensive disorders during pregnancy, in childbirth and postpartum period. Preeclampsia. Eclampsia» (protocol of treatment). [Klinicheskie rekomendacii «Gipertenzivnye rasstrojstva vo vremya beremennosti, v rodah i poslerodovom periode. Preeklampsiya. Eklampsiya» (protokol lecheniya)]. Pis'mo Ministerstva zdravoohraneniya Rossijskoj Federacii ot 07.06.2016 № 15-4/10/2-3483 (in Russian). URL: http://mosgorzdrav.ru/ru-RU/science/default/download/112.html [Accessed: 22.05.2018].
31. Tranquilli A.L. Introduction to ISSHP new classification of preeclampsia. Pregnancy Hypertens. 2013; 3 (2): 58-9. DOI: 10.1016/j.preghy.2013.04.006.
32. The investigation and management of the small–for–gestational–age fetus. Green-top Guideline No. 31. London, UK: Royal College of Obstetricians and Gynecologists. 2013: 34 p.
33. Clinical recommendations «Premature birth» (protocol of treatment). [Klinicheskie rekomendacii «Prezhdevremennye rody» (protokol lecheniya)]. Pis'mo Ministerstva zdravoohraneniya Rossijskoj Federacii ot 17.12.2013 № 15-4/10/2-9480 (in Russian). URL: http://zdravorel.ru/arhiv/prejdevremennierodi_2013.pdf [Accessed: 22.05.2018].
34. De Vries J.I.P., van Pampus M.G., Hague W.M. et al. Low-molecular weight heparin added to aspirin in the prevention of recurrent early-onset pre-eclampsia in women with inheritable thrombophilia: the FRUIT-RCT. J Thromb Haemost. 2012; 10: 64-72. DOI: 10.1111/j.1538-7836.2011.04553.x.
35. Skeith L., Carrier M., Kaaja R. et al. Rodger A meta-analysis of low-molecular-weight heparin to prevent pregnancy loss in women with inherited thrombophilia Blood. 2016; 127 (13): 1650-5. DOI: 10.1182/blood-2015-12626739.
36. Groom K.M., McCowan L.M., Mackay L.K. et al. Enoxaparin for the prevention of preeclampsia and intrauterine growth restriction in women with a history: a randomized trial. Am J Obstet Gynecol. 2017; 216 (3): 296. e1-296. e14. DOI: 10.1016/j.ajog.2017.01.014.
Review
For citations:
Nikolaeva M.G., Momot A.P., Zainulina M.S., Momot K.A., Yasafova N.N. Heparin prophylaxis of gestational complications in women with Factor V Leiden mutation (GA genotype). Obstetrics, Gynecology and Reproduction. 2018;12(2):21-31. (In Russ.) https://doi.org/10.17749/2313-7347.2018.12.2.021-031
Views: 661
This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.
Email this article 
